Compare Biogen Inc (BIIB) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Freshworks Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Freshworks Inc trades at $11.97 (market cap $3.31B). The key difference: Biogen Inc is far larger — about 9.1× Freshworks Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | FRSH | |
|---|---|---|
Market Cap | $30.13B | $3.31B |
Sector | Health | Technology |
52-Week High | $216.63 | $13.97 |
52-Week Low | $128.93 | $6.88 |
Enterprise Value | $37.20B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Freshworks (FRSH) trades at $11.67, down 2.59% on the day, with a bullish technical signal from moving averages but a neutral RSI. The company reported strong Q2 2026 results, beating earnings estimates with $0.17 EPS, and achieved its first quarter of GAAP profitability in 2026. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience (EX) segment, which now represents 60% of ARR.
The outlook is positive, with a consensus price target of $16.50 implying significant upside. Key opportunities include AI monetization and public sector expansion via FedRAMP progress. Risks include high valuation multiples like a 40.22 EV/EBITDA and competitive pressure in the SaaS sector. Analyst sentiment is evenly split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
